H.C. Wainwright reiterates Legend Biotech stock rating on pipeline progress

Legend Biotech reported fourth-quarter revenue of about $306 million, beating Raymond James' $288 million estimate, while EPS of $(0.08) also topped expectations of $(0.10). Carvykti sales remained strong, with Legend's share at $306.3 million for Q4 and $1.03 billion for full-year 2025; Johnson & Johnson reported Q1 2026 worldwide Carvykti sales of $597 million. H.C. Wainwright reiterated a Buy rating and $50 target, while other firms also maintained bullish ratings despite some price-target trimming.

Analysis

The setup is less about a single quarter and more about the market starting to price a cleaner line of sight to durability: if the next data presentation confirms even modestly better depth/duration on the CAR-T platform, LEGN can re-rate from a “commercially interesting” story to a multi-asset pipeline story. That matters because the current debate is not whether CARVYKTI is working, but whether the franchise can keep expanding while the company avoids being valued as a single-product royalty stream. The incremental upside is largest if management can prove that addressable-line expansion is structurally underpenetrated, not just cyclical.

The second-order winner is JNJ, because better mix in later lines and a more efficient launch curve improve the odds that the asset stays ahead of discount-rate pressure and competitive encroachment. The weaker link is IQV-like prescription noise and channel normalization: if investors have been extrapolating short-term ordering volatility, the next few weeks may produce false negatives that create entry points. The bigger hidden risk is capacity and adoption elasticity — if ordering keeps outpacing manufacturing, the market may reward the headline growth but cap the multiple on fears of supply-driven revenue ceilings.

Near term, the stock is likely to trade on event risk rather than fundamentals: a strong readout or supportive regulatory commentary could lift LEGN another 15-25% in days, while any delay or merely incremental data could unwind a chunk of the recent move given how much optimism is already embedded. Over the next 3-6 months, the key question is not whether sales grow, but whether the market believes growth is repeatable enough to justify a premium to other commercial-stage cell therapy names. Consensus may be missing that the real catalyst is not approval alone, but a credible path to broader line adoption plus evidence that international mix can offset U.S. seasonality.

Key Decisions for Investors

• Maintain a tactical long LEGN into the expected data window, but size as a catalyst trade, not a core hold; use a 2-6 week horizon and trim into any 15-20% event pop because the stock has already re-rated on anticipation.
• Pair long LEGN / short a basket of slower-growing cell-therapy or launch-exposed biopharma names over 1-3 months to isolate execution alpha versus sector beta; the trade works if LEGN proves the market is underestimating duration and breadth.
• Buy LEGN call spreads into any pullback driven by channel-noise headlines, targeting a positive surprise over the next 1-2 months; structure risk-defined exposure given binary readout risk.
• For lower-beta exposure, hold JNJ versus the broader biotech basket: if LEGN’s asset continues to inflect, JNJ captures the downstream value with less single-name volatility and better downside protection.
• Avoid shorting IQV on this headline alone; any weakness is likely to be transient noise unless multiple data points confirm a real demand slowdown over the next 1-2 quarters.